Csl(OTC) CSLLY

Market Cap$59.35BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)+606%
5 Year-36%
1 Year-8%
1 Month-1%
$30.92
+1.24%
+0.38Today
Csl last closing stock price
MetricPriceDate
Last closeUSD 30.922026-10-05
Csl stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.37%USD 32.002026-09-28
1 month-0.89%USD 31.202026-09-04
3 month+44.51%USD 21.402026-07-07
Year to date+10.14%USD 28.072025-12-31
1 year-7.62%USD 33.472025-10-03
3 year-18.21%USD 37.812023-10-06
5 year-35.71%USD 48.092021-10-06
Since inception+606.05%USD 4.332008-11-19

Csl Financials at a Glance

Market Cap

$59.35BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

-$1.35

P/E Ratio

-22.85

Dividend

$0.72

Beta (Volatility)

0.68 (Low)

Price

$30.92

Volume

52,100

Open

$30.75

Previous Close

$30.92

Daily Range

$30.73 - $30.97

52-Week Range

$16.01 - $36.29

Estimated Earnings Date

N/A

CSLLY News

cellectis

Why Shares of uniQure Are Dropping Tuesday

James HalleySep 5, 2023
Plasma donation

Who Can Donate Plasma for COVID-19 Patients?

Brian Orelli, PhDJun 14, 2020
Coronavirus patient 2

CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy

Brian Orelli, PhDApr 8, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Csl

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring and CSL Seqirus. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The CSL Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.

Industry

Biotechnology

Sector

Health Care

Employees

29,000

CEO

Gordon Naylor, MBA, CPA

Website

www.csl.com.au

CSLLY Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-15.17%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-4.38%

Dividend Yield

2.34%

Payout Ratio

N/A

Stock Overview

Market Cap

$59.35BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.92B

Volume

52.10K

Avg. Volume

177.35K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Csl Performance Analysis

Csl annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 13,114,573,12825.4%
20242024-06-30USD 14,741,889,37912.4%
20252025-06-30USD 15,403,768,6024.5%
20262026-06-30USD 15,768,125,7072.4%
Csl annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD 1.15-3.4%
20242024-06-30USD 1.3718.4%
20252025-06-30USD 1.5412.8%
20262026-06-30USD -1.34N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$59.35BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About CSLLY

What is the current price of Csl?

Csl is trading at $30.92 per share.

What is the 52-week range for Csl?

Over the past 52 weeks, Csl has traded between $16.01 and $36.29.

How much debt does Csl have?

As of the most recent reporting period, Csl reported total debt of $10.90B.

How much cash does Csl have on hand?

Csl reported $1.51B in cash and cash equivalents in its most recent financial results.

What is Csl’s dividend yield?

Csl currently has a dividend yield of 2.34%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services